Nektar Therapeutics (0UNL.L)
USD 0.84
(0.63%)
USD 0.84
(0.63%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 112.62 Million USD | -0.18% |
| 2022 | 112.82 Million USD | -10.27% |
| 2021 | 125.73 Million USD | -7.8% |
| 2020 | 136.37 Million USD | -4.45% |
| 2019 | 142.73 Million USD | -42.2% |
| 2018 | 246.95 Million USD | 0.71% |
| 2017 | 245.2 Million USD | -0.2% |
| 2016 | 245.68 Million USD | 1.03% |
| 2015 | 243.18 Million USD | 88.31% |
| 2014 | 129.13 Million USD | -2.94% |
| 2013 | 133.04 Million USD | -2.6% |
| 2012 | 136.6 Million USD | 836.82% |
| 2011 | 14.58 Million USD | -93.71% |
| 2010 | 231.96 Million USD | -0.76% |
| 2009 | 233.75 Million USD | -0.66% |
| 2008 | 235.3 Million USD | -30.1% |
| 2007 | 336.63 Million USD | 0.56% |
| 2006 | 334.75 Million USD | -23.56% |
| 2005 | 437.92 Million USD | 121.72% |
| 2004 | 197.51 Million USD | -49.57% |
| 2003 | 391.67 Million USD | 18.33% |
| 2002 | 331.01 Million USD | -0.01% |
| 2001 | 331.05 Million USD | 3.69% |
| 2000 | 319.26 Million USD | 181.68% |
| 1999 | 113.34 Million USD | 2194.43% |
| 1998 | 4.94 Million USD | -3.18% |
| 1997 | 5.1 Million USD | 2451.0% |
| 1996 | 200 Thousand USD | -50.0% |
| 1995 | 400 Thousand USD | -20.0% |
| 1994 | 500 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 107.5 Million USD | -100.0% |
| 2024 Q1 | 117.85 Million USD | 0.0% |
| 2023 Q2 | 105.81 Million USD | -3.27% |
| 2023 Q3 | 102.19 Million USD | -3.42% |
| 2023 Q4 | 112.62 Million USD | 10.21% |
| 2023 Q1 | 109.38 Million USD | -3.05% |
| 2023 FY | 112.62 Million USD | -0.18% |
| 2022 Q4 | 112.82 Million USD | -2.86% |
| 2022 Q1 | 122.63 Million USD | -2.46% |
| 2022 FY | 112.82 Million USD | -10.27% |
| 2022 Q3 | 116.14 Million USD | -2.74% |
| 2022 Q2 | 119.41 Million USD | -2.63% |
| 2021 Q4 | 125.73 Million USD | -2.32% |
| 2021 FY | 125.73 Million USD | -7.8% |
| 2021 Q1 | 134.55 Million USD | -1.33% |
| 2021 Q2 | 131.65 Million USD | -2.15% |
| 2021 Q3 | 128.71 Million USD | -2.23% |
| 2020 Q4 | 136.37 Million USD | -1.91% |
| 2020 Q2 | 141.63 Million USD | -0.47% |
| 2020 Q3 | 139.02 Million USD | -1.84% |
| 2020 Q1 | 142.29 Million USD | -0.3% |
| 2020 FY | 136.37 Million USD | -4.45% |
| 2019 Q4 | 142.73 Million USD | -63.71% |
| 2019 FY | 142.73 Million USD | -42.2% |
| 2019 Q1 | 342.41 Million USD | 38.66% |
| 2019 Q2 | 342.64 Million USD | 0.07% |
| 2019 Q3 | 393.35 Million USD | 14.8% |
| 2018 Q4 | 246.95 Million USD | 0.18% |
| 2018 Q1 | 245.64 Million USD | 0.18% |
| 2018 Q3 | 246.51 Million USD | 0.18% |
| 2018 FY | 246.95 Million USD | 0.71% |
| 2018 Q2 | 246.07 Million USD | 0.18% |
| 2017 Q1 | 245.5 Million USD | -0.07% |
| 2017 FY | 245.2 Million USD | -0.2% |
| 2017 Q4 | 245.2 Million USD | 0.18% |
| 2017 Q3 | 244.77 Million USD | -0.25% |
| 2017 Q2 | 245.39 Million USD | -0.05% |
| 2016 Q3 | 245.14 Million USD | -0.07% |
| 2016 FY | 245.68 Million USD | 1.03% |
| 2016 Q2 | 245.32 Million USD | -0.05% |
| 2016 Q1 | 245.45 Million USD | 0.93% |
| 2016 Q4 | 245.68 Million USD | 0.22% |
| 2015 FY | 243.18 Million USD | 88.31% |
| 2015 Q1 | 129.38 Million USD | 0.19% |
| 2015 Q2 | 127.88 Million USD | -1.16% |
| 2015 Q3 | 1.33 Million USD | -98.96% |
| 2015 Q4 | 243.18 Million USD | 18116.33% |
| 2014 Q3 | 130.33 Million USD | -0.52% |
| 2014 Q2 | 131.02 Million USD | -0.78% |
| 2014 Q1 | 132.05 Million USD | -0.75% |
| 2014 Q4 | 129.13 Million USD | -0.92% |
| 2014 FY | 129.13 Million USD | -2.94% |
| 2013 Q3 | 134 Million USD | -0.66% |
| 2013 Q1 | 135.76 Million USD | -0.62% |
| 2013 Q4 | 133.04 Million USD | -0.71% |
| 2013 FY | 133.04 Million USD | -2.6% |
| 2013 Q2 | 134.9 Million USD | -0.64% |
| 2012 Q1 | 13.89 Million USD | -4.75% |
| 2012 FY | 136.6 Million USD | 836.82% |
| 2012 Q4 | 136.6 Million USD | -0.59% |
| 2012 Q3 | 137.41 Million USD | 943.07% |
| 2012 Q2 | 13.17 Million USD | -5.15% |
| 2011 Q1 | 231.4 Million USD | -0.24% |
| 2011 FY | 14.58 Million USD | -93.71% |
| 2011 Q4 | 14.58 Million USD | -4.38% |
| 2011 Q3 | 15.25 Million USD | -93.39% |
| 2011 Q2 | 230.81 Million USD | -0.25% |
| 2010 Q1 | 233.3 Million USD | -0.19% |
| 2010 FY | 231.96 Million USD | -0.76% |
| 2010 Q3 | 232.35 Million USD | -0.21% |
| 2010 Q2 | 232.84 Million USD | -0.2% |
| 2010 Q4 | 231.96 Million USD | -0.17% |
| 2009 Q4 | 233.75 Million USD | -0.18% |
| 2009 Q2 | 234.57 Million USD | -0.16% |
| 2009 FY | 233.75 Million USD | -0.66% |
| 2009 Q1 | 234.94 Million USD | -0.15% |
| 2009 Q3 | 234.18 Million USD | -0.17% |
| 2008 Q1 | 336.33 Million USD | -0.09% |
| 2008 FY | 235.3 Million USD | -30.1% |
| 2008 Q2 | 336.01 Million USD | -0.09% |
| 2008 Q3 | 335.68 Million USD | -0.1% |
| 2008 Q4 | 235.3 Million USD | -29.9% |
| 2007 Q4 | 336.63 Million USD | -0.11% |
| 2007 FY | 336.63 Million USD | 0.56% |
| 2007 Q1 | 334.54 Million USD | -0.06% |
| 2007 Q2 | 334.32 Million USD | -0.07% |
| 2007 Q3 | 336.98 Million USD | 0.8% |
| 2006 FY | 334.75 Million USD | -23.56% |
| 2006 Q1 | 401.75 Million USD | -8.26% |
| 2006 Q4 | 334.75 Million USD | -16.61% |
| 2006 Q3 | 401.44 Million USD | -0.04% |
| 2006 Q2 | 401.6 Million USD | -0.04% |
| 2005 Q4 | 437.92 Million USD | -0.03% |
| 2005 Q1 | 194.59 Million USD | -1.48% |
| 2005 FY | 437.92 Million USD | 121.72% |
| 2005 Q2 | 194.48 Million USD | -0.06% |
| 2005 Q3 | 438.07 Million USD | 125.25% |
| 2004 Q2 | 204.42 Million USD | -3.93% |
| 2004 FY | 197.51 Million USD | -49.57% |
| 2004 Q4 | 197.51 Million USD | -0.09% |
| 2004 Q3 | 197.69 Million USD | -3.29% |
| 2004 Q1 | 212.77 Million USD | -45.67% |
| 2003 Q4 | 391.67 Million USD | -6.56% |
| 2003 Q3 | 419.19 Million USD | 2.32% |
| 2003 Q2 | 409.69 Million USD | 23.91% |
| 2003 Q1 | 330.63 Million USD | -0.11% |
| 2003 FY | 391.67 Million USD | 18.33% |
| 2002 Q4 | 331.01 Million USD | -0.14% |
| 2002 Q2 | 330.95 Million USD | 0.04% |
| 2002 Q1 | 330.82 Million USD | -0.07% |
| 2002 Q3 | 331.49 Million USD | 0.16% |
| 2002 FY | 331.01 Million USD | -0.01% |
| 2001 Q3 | 328.76 Million USD | 1.01% |
| 2001 Q4 | 331.05 Million USD | 0.7% |
| 2001 FY | 331.05 Million USD | 3.69% |
| 2001 Q1 | 317.94 Million USD | -0.42% |
| 2001 Q2 | 325.48 Million USD | 2.37% |
| 2000 Q2 | 242.63 Million USD | -0.82% |
| 2000 Q4 | 319.26 Million USD | 31.59% |
| 2000 Q1 | 244.64 Million USD | 115.84% |
| 2000 Q3 | 242.62 Million USD | -0.0% |
| 2000 FY | 319.26 Million USD | 181.68% |
| 1999 Q2 | 4.91 Million USD | -0.16% |
| 1999 Q3 | 4.9 Million USD | -0.26% |
| 1999 Q4 | 113.34 Million USD | 2211.28% |
| 1999 FY | 113.34 Million USD | 2194.43% |
| 1999 Q1 | 4.92 Million USD | -0.3% |
| 1998 Q4 | 4.94 Million USD | -0.34% |
| 1998 Q2 | 4.97 Million USD | -2.24% |
| 1998 FY | 4.94 Million USD | -3.18% |
| 1998 Q1 | 5.08 Million USD | -0.27% |
| 1998 Q3 | 4.95 Million USD | -0.34% |
| 1997 Q4 | 5.1 Million USD | 3347.3% |
| 1997 Q1 | 175 Thousand USD | -12.5% |
| 1997 FY | 5.1 Million USD | 2451.0% |
| 1997 Q2 | 162 Thousand USD | -7.43% |
| 1997 Q3 | 148 Thousand USD | -8.64% |
| 1996 Q3 | 200 Thousand USD | -33.33% |
| 1996 FY | 200 Thousand USD | -50.0% |
| 1996 Q1 | 300 Thousand USD | -25.0% |
| 1996 Q4 | 200 Thousand USD | 0.0% |
| 1996 Q2 | 300 Thousand USD | 0.0% |
| 1995 FY | 400 Thousand USD | -20.0% |
| 1995 Q1 | 400 Thousand USD | -20.0% |
| 1995 Q2 | 300 Thousand USD | -25.0% |
| 1995 Q3 | 300 Thousand USD | 0.0% |
| 1995 Q4 | 400 Thousand USD | 33.33% |
| 1994 FY | 500 Thousand USD | 0.0% |
| 1994 Q3 | - USD | -100.0% |
| 1994 Q4 | 500 Thousand USD | 0.0% |
| 1994 Q1 | 600 Thousand USD | 0.0% |
| 1994 Q2 | 600 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | 13.409% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -97.629% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 70.962% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -146.482% |
| bluebird bio, Inc. | 224.41 Million USD | 49.815% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -203.743% |
| Imunon, Inc. | 1.13 Million USD | -9785.517% |
| Editas Medicine, Inc. | 24.37 Million USD | -362.108% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.131% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 94.299% |
| Myriad Genetics, Inc. | 130.9 Million USD | 13.961% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 56.398% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -239.273% |
| Verastem, Inc. | 40.08 Million USD | -180.958% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 98.6% |
| Waters Corporation | 2.3 Billion USD | 95.115% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.64% |
| Biogen Inc. | 7.18 Billion USD | 98.433% |
| Perrigo Company plc | 3.63 Billion USD | 96.9% |
| Dynavax Technologies Corporation | 252.41 Million USD | 55.382% |
| Illumina, Inc. | 1.48 Billion USD | 92.436% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -3377.55% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -11162.5% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 35.181% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -378.461% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 81.011% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -236.044% |
| Evolus, Inc. | 120.35 Million USD | 6.426% |
| Adicet Bio, Inc. | 17.7 Million USD | -536.192% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -3563.793% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 95.833% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 77.544% |
| FibroGen, Inc. | 89.69 Million USD | -25.562% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 95.882% |
| OPKO Health, Inc. | 222.03 Million USD | 49.276% |
| Homology Medicines, Inc. | 43.17 Million USD | -160.851% |
| Geron Corporation | 35.05 Million USD | -221.318% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 95.193% |
| Exelixis, Inc. | 189.94 Million USD | 40.706% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -11932.585% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -16.412% |
| Zoetis Inc. | 6.56 Billion USD | 98.284% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 36.752% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -2458.496% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 84.459% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -229.409% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 91.958% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 90.055% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 92.488% |
| Blueprint Medicines Corporation | 610.96 Million USD | 81.566% |
| Insmed Incorporated | 1.19 Billion USD | 90.562% |
| TG Therapeutics, Inc. | 100.11 Million USD | -12.492% |
| Incyte Corporation | 29.16 Million USD | -286.205% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 74.776% |